200
Participants
Start Date
May 31, 2004
Primary Completion Date
March 31, 2008
Study Completion Date
March 31, 2008
hCRF
hCRF ; open-label dexamethasone that the patient is currently taking
placebo hCRF
placebo hCRF 2mg/day and open-label dexamethasone that they are taking
Memorial Sloan Kettering Cancer Center, New York
Weill Medical College of Cornell University, New York
Dent Neurologic Institute, Amherst
Winship Cancer Institute, Emory University, Atlanta
Mayo Clinic, Jacksonville
Cancer Institute of Orlando, Orlando
University Hematology Oncology Care, LLC, Cincinnati
The Ohio State University, Columbus
Good Samaritan Hospital, Cincinnati
Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit
University of Wisconsin, Madison
Evanston Northwestern Healthcare, Evanston
Northwestern University, Feinberg School of Medicine, Chicago
University of Colorado Cancer Center, Aurora
Colorado Neurological Institute, Englewood
Barrow Neurological Institute, Phoenix
UC San Diego, Thornton Hospital, San Diego
Hoag Memorial Hospital Presbyterian, Newport Beach
UCSF Fresno Center for Clinical Studies, Fresno
Stanford University Medical Center, Palo Alto
UC Davis Medical Center, Division of Medical Oncology, Sacramento
Oregon Clinic, Portland
Virginia Mason Clinic, Seattle
Moffitt Cancer Center & Research Institute, Tampa
Beth Israel Deaconess Medical Center, Boston
Neurology Group of Bergen County, Ridgewood
Medical College of Wisconsin, Milwaukee
Cross Cancer Institute, Edmonton
CancerCare Manitoba, Winnipeg
The Moncton Hospital, Moncton
Queen Elizabeth II Health Sciences Center, Halifax
Kingston General Hospital, Kingston
Ottawa Regional Cancer Centre, Ottawa
Sunnybrook and Women's College Health, Toronto
Lead Sponsor
Collaborators (1)
Neurobiological Technologies
INDUSTRY
Celtic Pharma Development Services
INDUSTRY